Updates and Statements | Pfizer

Skip to main content

Science
Products
Stories
Newsroom
About

Investors Careers Media Partners

Careers
Investors

How can we help you?

4602 search results for

Suggestions within Pfizer.com

Home

Newsroom

Updates and Statements

Updates and Statements

Year

2023

2022

2021

2020

2019

2018

2017

2016

2015

2014

2013

2012

2011

2010

2009

2008

2007

Month

January

February

March

April

May

June

July

August

September

October

November

December

View 12

View 24

View 48

Keywords

All Keywords

January 2023

01.27.2023 Covid-19Medicines Pfizer Receives Positive CHMP Opinion for Conversion of PAXLOVID™ Conditional Marketing Authorization to Full Marketing Authorization in the European Union
01.17.2023 Investments Pfizer to Acquire Sanford, North Carolina Manufacturing Site from Abzena

December 2022

12.22.2022 Medicines Hospira, Inc. Issues A Voluntary Nationwide Recall For One Lot of Vancomycin Hydrochloride Injection, USP 1.5g/vial, Due To The Presence of Visible Glass Particulates
12.20.2022 Medicines U.S. FDA Extends Review of Pfizer’s New Drug Application for PAXLOVID™
12.13.2022 Covid-19MedicinesPartnerships Pfizer to Provide U.S. Government with an Additional 3.7 Million Treatment Courses of PAXLOVID™ to Help Combat COVID-19
12.09.2022 ResearchVaccines Pfizer and BioNTech Receive U.S. FDA Fast Track Designation for Single-Dose mRNA-Based Vaccine Candidate Against COVID-19 and Influenza

November 2022

11.23.2022 Covid-19Medicines Pfizer Signs Agreement to Provide the European Union with PAXLOVID™
11.16.2022 Covid-19ResearchVaccines Pfizer and BioNTech Advance Next-Generation COVID-19 Vaccine Strategy with Study Start of Candidate Aimed at Enhancing Breadth of T cell Responses and Duration of Protection
11.03.2022 Covid-19ResearchVaccines Pfizer and BioNTech Initiate Phase 1 Study of Single Dose mRNA-Based Combination Vaccine Candidate for Influenza and COVID-19

October 2022

10.28.2022 Medicines Safety Recommendation on Janus kinase (JAK) Inhibitors Issued in the European Union
10.20.2022 Vaccines Advisory Committee on Immunization Practices Recommends Pfizer’s PREVNAR 20® for Adults Previously Vaccinated with PREVNAR 13®
10.19.2022 Covid-19Vaccines Pfizer and BioNTech Receive Positive CHMP Opinion for COMIRNATY® in Children 6 Months to less than 5 Years in the European Union

Page 1
Current page 2
Page 3
Page 4
Page 5

Investors
Careers
Media
Partners

Grant Seekers
Healthcare Professionals
Business to Business
Merchandise

Privacy Statement
Terms of Use
Contact Us

© 2023 Pfizer Inc. All rights reserved

This information—including product information—is intended only for residents of the United States.

The products discussed herein may have different labeling in different countries.

Twitter
Facebook
Linked In
Instagram
Youtube